scPharmaceuticals Inc.

NasdaqGS:SCPH Stok Raporu

Piyasa değeri: US$203.6m

scPharmaceuticals Temettü

Temettü kriter kontrolleri 0/6

scPharmaceuticals does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-0.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi-0.4%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Oct 10

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Aug 26

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Mar 09
Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Nov 24
How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if SCPH's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if SCPH's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

scPharmaceuticals Piyasaya Karşı Temettü Getirisi
SCPH temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (SCPH)n/a
Pazarın Alt %25'i (US)1.5%
Pazarın En İyi %25'i (US)4.5%
Sektör Ortalaması (Pharmaceuticals)2.3%
Analist tahmini (SCPH) (3 yıla kadar)n/a

Önemli Temettü: Unable to evaluate SCPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate SCPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate SCPH's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as SCPH has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin